National Institutes of Health

Mount Sinai's The Louis Armstrong Center for Music and Medicine Celebrates 30th Anniversary With a Commemorative Conference

Retrieved on: 
onsdag, maj 29, 2024
Community health, Partnership, Indiana University, Doctor of Philosophy, Bangladesh Technical Education Board, Health, Patient, Pediatrics, International Association, National Institutes of Health, Depression, DA, Mental health, Conference, Assessment, Music, Ageing, MD, AI, Research, Cancer, Medical director, Music therapy, LCAT, Nursing, Pearl of Wisdom, Mount Sinai Health System, NIH

New York, NY, May 29, 2024 (GLOBE NEWSWIRE) -- The Louis Armstrong Center for Music and Medicine at Mount Sinai is celebrating its 30th anniversary.

Key Points: 
  • New York, NY, May 29, 2024 (GLOBE NEWSWIRE) -- The Louis Armstrong Center for Music and Medicine at Mount Sinai is celebrating its 30th anniversary.
  • Launched with support from the Louis Armstrong Educational Foundation, the Center created a new model of integrating music and medicine in patient care and has served patients and families in various settings throughout the Mount Sinai Health System and overseas.
  • Conference sponsors include the Renee Fleming Foundation, Marshalls Speakers, the MJS Foundation, and the International Association for Music and Medicine.
  • Joanne Loewy, DA, is a Professor of Family Medicine and Community Health at the Icahn School of Medicine at Mount Sinai and Director of the Center.

ATCC Announces Award from NIAID to Provide Antiviral Screening Assays Relevant to Human Diseases

Retrieved on: 
onsdag, maj 29, 2024
Infectious Diseases, Biotechnology, Health, Clinical Trials, Human services, Bangladesh Technical Education Board, Doctor of Philosophy, NIAID, Infection, COVID-19, Instability, WCCM, National Institutes of Health, Engineering, MBA, Senior, DVM, Government, BSL, Virus, NIH, Vaccine

Under this task order 75N93019D00002-75N93024F00001, ATCC will develop well-characterized challenge material (WCCM) for the In Vitro Assessment for Antimicrobial Activity (IVAAA) program.

Key Points: 
  • Under this task order 75N93019D00002-75N93024F00001, ATCC will develop well-characterized challenge material (WCCM) for the In Vitro Assessment for Antimicrobial Activity (IVAAA) program.
  • This program aims to evaluate candidate countermeasures against microbial pathogens and vectors, including those derived from clinical specimens.
  • The assessments are conducted in vitro and focus on antiviral screening assays for biosafety level (BSL)-3/4 viruses relevant to human diseases, as well as other rapidly emerging viruses that employ similar assay methodologies.
  • Ensuring the genomic homogeneity of WCCM, as well as improving the production capacity of WCCM used in drug screening studies, is essential for therapeutic drug development.

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

Retrieved on: 
tisdag, maj 28, 2024
ACT, CNM, Bangladesh Technical Education Board, Survival, NINDS, EAP, Risk, National Institutes of Health, FDA, Trial of the century, Safety, FAAN, Natural history, ALS, DSM-IV codes, Principal investigator, Multiple sclerosis, Death, Research, Columbia University, Biomarker, NIH, Master of Science, Pharmaceutical industry

In recognizing the need for accessibility and inclusion in such programs for individuals with ALS, Clene instituted significant manufacturing, operational, and personnel efficiencies to expand the program’s accommodation to up to 180 participants.

Key Points: 
  • In recognizing the need for accessibility and inclusion in such programs for individuals with ALS, Clene instituted significant manufacturing, operational, and personnel efficiencies to expand the program’s accommodation to up to 180 participants.
  • “The Clene team recognized that there was great need in the ALS community for more access to promising treatments,” Austin Rynders, VP Clinical Operations at Clene, reflected on this effort.
  • “By leveraging our telehealth platform, Synapticure extends the reach of expanded access programs to people throughout the US.
  • With a nationwide presence, we enable people living with ALS access to investigational medicines like CNM-Au8 who have not previously had the option."

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

Retrieved on: 
onsdag, maj 15, 2024
FDA, GSK, Fast Track, NTM, Unitary state, Research, G&A, Bangladesh Technical Education Board, NIAID, Infection, AP, Pseudomonas aeruginosa, Acinetobacter baumannii, Army, Human services, Urinary tract infection, Clinical trial, National Institutes of Health, Safety, MDR, Pyelonephritis, Administration, Department of Defence, Policy, Mycobacterium avium complex, Patient, Pharmacokinetics, Therapy, Assistant, HBR, Tebipenem, Federal, Government, Quality of life, Pharmaceutical industry

Supported by a strong balance sheet, Spero remains well capitalized with expected cash runway into late 2025.”

Key Points: 
  • Supported by a strong balance sheet, Spero remains well capitalized with expected cash runway into late 2025.”
    Top-line data from the Phase 2a proof-of-concept clinical trial are expected in 2H 2024.
  • Total revenue for the first quarter of 2024 was $9.3 million, compared with total revenue of $2.1 million for the first quarter of 2023.
  • General and administrative expenses for the first quarter of 2024 were $5.9 million, compared to $7.3 million for the same period in 2023.
  • As of March 31, 2024, Spero had cash and cash equivalents of $82.3 million, compared to $76.3 million at December 31, 2023.

Thought Leadership & Innovation Foundation Chairman and President, Bill Oldham Featured on One World Initiative Public Broadcast: Innovation Improves Access to Healthcare, Improves Outcomes

Retrieved on: 
tisdag, maj 14, 2024
Software, Research, Managed Care, Pharmaceutical, Telemedicine, Virtual Medicine, Data Management, Technology, Health Technology, Clinical Trials, Science, Practice Management, Health, Knowledge, Clinical professor, Partnership, Amputation, Patient, Bangladesh Technical Education Board, Mayo Clinic, Macular degeneration, Interview, National Institutes of Health, Public policy, Conditional sentence, OWI, Public, Mental health, TLI, Artificial intelligence, Telehealth, NIH, Pharmaceutical industry

A nonprofit global public broadcast organization, OWI increases cooperation worldwide through broadcast programming, integrated media, printed materials and international events.

Key Points: 
  • A nonprofit global public broadcast organization, OWI increases cooperation worldwide through broadcast programming, integrated media, printed materials and international events.
  • “Access to quality healthcare is a fundamental human right, and TLI is dedicated to driving innovation to ensure that everyone, regardless of their background or circumstances, has access to the care they need.
  • He also highlights the importance of telemedicine and patient portals in making healthcare more accessible and convenient for patients.
  • “I am extremely optimistic about the future of healthcare and growing awareness of the importance of nutrition, activity and mental health,” he shares.

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
onsdag, maj 8, 2024
Infection, Congress, Candida glabrata, Investment, Mouse, Data analysis, NIH, Fungal infection, Research, ECCMID, Clinical trial, FURI, GSK, Antimalarial medication, Patient, Candidiasis, CMC, Chemistry, National Institutes of Health, Candida auris, Biotechnology, Mucorales, Pharmaceutical industry

Phase I-enabling development activities for SCY-247, the second generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to progress.

Key Points: 
  • Phase I-enabling development activities for SCY-247, the second generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to progress.
  • Research and development expense for the quarter ended March 31, 2024 was $7.2 million compared to $6.8 million for the same period in 2023.
  • SG&A expense for the quarter ended March 31, 2024 decreased to $3.7 million from $4.8 million for the same period in 2023.
  • Cash, cash equivalents and investments totaled $94.2 million on March 31, 2024, compared to $98.0 million on December 31, 2023.

Milken Institute Announces Key Initiatives at the 2024 Global Conference to Shape the Future of Health

Retrieved on: 
tisdag, maj 7, 2024
Professional Services, Health, Other Health, Human Resources, General Health, Research, Science, Project, Mayo Clinic, Investment, Milken Institute, Risk, Substance use disorder, Partnership, Employment, Crowding, Private sector, Health policy, Public, Bangladesh Technical Education Board, Community health, Food, Conference, MITRE, Society, GSK, Obesity, Collaboration, Heart, Eli Lilly, Digital, National Institutes of Health, Multimedia, Organization, Walmart, Public health, Workflow, Disease, Food and Drug Administration, Chronic condition

The Milken Institute announced new initiatives to shape the future of health through partnerships and collaboration at its 2024 Global Conference in Los Angeles.

Key Points: 
  • The Milken Institute announced new initiatives to shape the future of health through partnerships and collaboration at its 2024 Global Conference in Los Angeles.
  • View the full release here: https://www.businesswire.com/news/home/20240507245811/en/
    Esther Krofah (left), executive vice president of Milken Institute Health, with Emma Walmsley (right), CEO of GSK, at the 2024 Milken Institute Global Conference.
  • (Photo: Business Wire)
    “Working together with our partners and collaborators, the Milken Institute is committed to advancing solutions that bridge the gaps across the health, public health, and health care continuum to increase access to innovation and improve health outcomes," said Esther Krofah , executive vice president of Milken Institute Health.
  • This includes its Alliance to Improve Dementia Care , and programs from FasterCures , Public Health , Future of Aging , and Feeding Change , among other health initiatives.

New PRI Brief: JAMA Study Justifying Drug Price Controls Deeply Flawed, Patient Health Jeopardized if Findings Implemented

Retrieved on: 
onsdag, maj 8, 2024
FDA, Patient, Bangladesh Technical Education Board, Sanders, Risk, JAMA, Health, American Medical Association, Innovation, Research, Pacific Research Institute, Policy, Sustainability, National Institutes of Health, Medicare, Congressional Budget Office, Multimedia, Drug development, PRI, Biotechnology, Medical device

To justify price controls, Sanders cites the JAMA study ("Estimated Sustainable Cost-Based Prices for Diabetes Medicines" by Barber, Gotham and Bygrave) claiming innovative diabetes medicines can be manufactured for $5 a month.

Key Points: 
  • To justify price controls, Sanders cites the JAMA study ("Estimated Sustainable Cost-Based Prices for Diabetes Medicines" by Barber, Gotham and Bygrave) claiming innovative diabetes medicines can be manufactured for $5 a month.
  • Winegarden and Pipes identify numerous flaws that invalidate the study's results and highlight how the Sanders agenda would put patient health at risk.
  • In one identified flaw, the JAMA authors do not adequately define excessive profits, despite it being their study's central premise.
  • Winegarden and Pipes argue the authors would consider recouping drug innovation costs in setting prices to be "excessive."

Leading Radiation Oncologist Dr. Steven E. Finkelstein Joins Associated Medical Professionals of NY, an Affiliate of U.S. Urology Partners

Retrieved on: 
tisdag, april 30, 2024
Medical Supplies, Biotechnology, Practice Management, Managed Care, Health, General Health, Radiology, Oncology, Medical Devices, Hospitals, Clinical Trials, Corporation, Micron Technology, University, Bangladesh Technical Education Board, Kidney, Hospital, Clinical research, Breast, National Cancer Institute, NMS, Literature, CARE, Prostate cancer, Radiation therapy, Patient, National Institutes of Health, Medicine, Physician, Lung, Radiation, Cancer, Medical imaging

Associated Medical Professionals of NY spans 18 locations in Central New York, including nine offices and nine hospitals.

Key Points: 
  • Associated Medical Professionals of NY spans 18 locations in Central New York, including nine offices and nine hospitals.
  • Radiation Oncology is the region’s leading provider of comprehensive cancer care services, providing the most advanced, effective treatments available for urological and other types of cancers.
  • Steven Finkelstein’s extensive experience in radiation oncology care and his leadership in the medical field will be a tremendous asset to U.S. Urology Partners, Associated Medical Professionals of NY and most importantly to individuals receiving cancer care in the Central New York region.
  • I am excited to join the team of Associated Medical Professionals of NY and look forward to helping patients in the community.”

Immunome Appoints Sandra M. Swain to Board of Directors

Retrieved on: 
torsdag, april 25, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, MedStar Health, University, Bangladesh Technical Education Board, Pfizer, Genetic distance, Professor, Vanderbilt University, Doctor of Philosophy, National Cancer Institute, Dean (education), IND, ASCO, Patient, National Institutes of Health, Society, Acquisition, Executive Committee, Georgetown University Medical Center, Internal medicine, Investigational New Drug

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors.

Key Points: 
  • Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors.
  • “Immunome is pleased to welcome Sandra to the Board of Directors, especially given her extensive experience as a successful clinical researcher,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
  • Dr. Swain served on the board of directors of the American Society of Clinical Oncology (ASCO) from 2008-2013 and was ASCO President 2012-13.
  • Dr. Swain previously served on the board of directors of Seagen Inc. from November 2022 until its acquisition by Pfizer Inc. in December 2023.